Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017

Details for Mechanism ID: 16678
Country/Region: Malawi
Year: 2014
Main Partner: Management Sciences for Health
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $2,875,000 Additional Pipeline Funding: N/A

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

The objective of this mechanism is to improve the quality, coverage and access of HIV (and related) services for 2.6 million people in 7 districts (Likoma, Nkhata Bay, Blantyre, Mwanza, Neno, Chiradzulu and Thyolo) in Malawi.

On the basis of programmatic data (collected through quarterly supervision by the Department of HIV and AIDS in the Ministry of Health), other reports and data collected by zonal and district health authorities and specific assessments, a continuous assessment and analysis of performance of health services in all health facilities is done. We plan targeted interventions and implement in close coordination with zonal and district health authorities and other implementing partners.

We will specifically support HIV-related supervision and mentoring activities and provide direct support to the implementation through in-service training, provision of medical equipment and furniture, and rehabilitation of decrepit health facilities. We will support measures to increase the identification and linkage of PLHIV into care, improve the quality of services rendered, and increase retention in care. In addition, we will strengthen health systems by bringing staff levels in hard-to-reach health facilities to minimum levels, support drug supply chain management systems, and support diagnostics and laboratories.

We will increase the cost efficiency over time as capacity of the districts will increase and a larger proportion of the available resources will directly support HIV activities in the district. This transition is effected through increasing the volume of sub-grants to the districts and sub-contracts to local CBOs.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $454,000
Care: TB/HIV (HVTB) $124,000
Care: Pediatric Care and Support (PDCS) $354,000
Laboratory Infrastructure (HLAB) $62,000
Health Systems Strengthening (OHSS) $60,000
Testing: HIV Testing and Counseling (HVCT) $47,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $600,000
Treatment: Adult Treatment (HTXS) $1,018,497
Treatment: Pediatric Treatment (PDTX) $155,503
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
C2.4.D Number of HIV-positive patients who were screened for TB in HIV care or treatment setting 2015 1
C2.5.D Number of HIV-positive patients in HIV care who started TB treatment 2015 30
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 69,867
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 11,708
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 110,540
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 7,404
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 199,519
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2015 199,519
CARE_NEW Aggregated Age/sex: <15 Female 2015 2,751
CARE_NEW Aggregated Age/sex: <15 Male 2015 2,751
CARE_NEW Aggregated Age/sex: 15+ Female 2015 30,809
CARE_NEW Aggregated Age/sex: 15+ Male 2015 18,704
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 55,015
CARE_NEW Sum of Aggregated Age/sex disaggregates 2015 55,015
HTS_TST Age/sex: <1 Female 2015 6,020
HTS_TST Age/sex: <1 Female 2015 8,646
HTS_TST Age/sex: <1 Male 2015 2,965
HTS_TST Age/sex: <1 Male 2015 4,258
HTS_TST Age/sex: 1-4 Female 2015 27,092
HTS_TST Age/sex: 1-4 Female 2015 38,908
HTS_TST Age/sex: 1-4 Male 2015 13,344
HTS_TST Age/sex: 1-4 Male 2015 19,164
HTS_TST Age/sex: 10-14 Female 2015 42,142
HTS_TST Age/sex: 10-14 Female 2015 60,522
HTS_TST Age/sex: 10-14 Male 2015 20,756
HTS_TST Age/sex: 10-14 Male 2015 29,809
HTS_TST Age/sex: 15-19 Female 2015 69,234
HTS_TST Age/sex: 15-19 Female 2015 99,430
HTS_TST Age/sex: 15-19 Male 2015 34,100
HTS_TST Age/sex: 15-19 Male 2015 48,973
HTS_TST Age/sex: 20-24 Female 2015 81,274
HTS_TST Age/sex: 20-24 Female 2015 116,721
HTS_TST Age/sex: 20-24 Male 2015 40,031
HTS_TST Age/sex: 20-24 Male 2015 57,490
HTS_TST Age/sex: 25-49 Female 2015 36,122
HTS_TST Age/sex: 25-49 Female 2015 51,877
HTS_TST Age/sex: 25-49 Male 2015 17,792
HTS_TST Age/sex: 25-49 Male 2015 25,551
HTS_TST Age/sex: 5-9 Female 2015 36,122
HTS_TST Age/sex: 5-9 Female 2015 51,877
HTS_TST Age/sex: 5-9 Male 2015 17,792
HTS_TST Age/sex: 5-9 Male 2015 25,551
HTS_TST Age/sex: 50+ Female 2015 3,011
HTS_TST Age/sex: 50+ Female 2015 4,324
HTS_TST Age/sex: 50+ Male 2015 1,483
HTS_TST Age/sex: 50+ Male 2015 2,130
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 111,376
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 54,857
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 189,641
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 93,406
HTS_TST Aggregated Age/sex: <15 Female 2015 159,953
HTS_TST Aggregated Age/sex: <15 Male 2015 78,782
HTS_TST Aggregated Age/sex: 15+ Female 2015 272,352
HTS_TST Aggregated Age/sex: 15+ Male 2015 134,144
HTS_TST By Test Result: Negative 2015 395,366
HTS_TST By Test Result: Negative 2015 567,802
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 449,280
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 645,230
HTS_TST Sum of Age/Sex disaggregates 2015 449,280
HTS_TST Sum of Age/Sex disaggregates 2015 645,231
HTS_TST Sum of Aggregated Age/Sex <15 2015 166,233
HTS_TST Sum of Aggregated Age/Sex <15 2015 238,735
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 283,047
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 406,496
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 449,280
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 645,231
HTS_TST Sum of Test Result disaggregates 2015 449,280
HTS_TST Sum of Test Result disaggregates 2015 645,230
HTS_TST_POS By Test Result: Positive 2015 53,914
HTS_TST_POS By Test Result: Positive 2015 77,428
LAB_ACC By site support type: Technical Assistance-only (TA) 2015 100
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2015 12
LAB_ACC Sum of Support Type disaggregates 2015 100
LAB_CAP By clinical laboratories 2015 12
LAB_CAP By Point-of-care testing sites 2015 5
LAB_CAP By site support type: Technical Assistance-only (TA) 2015 17
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 17
LAB_CAP Sum of Site Support Type disaggregates 2015 17
PMTCT_ARV Life-long ART (including Option B+) 2015 9,218
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 10,241
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 9,218
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 3,597
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 5,623
PMTCT_ARV Sum of New and Current disaggregates 2015 9,220
PMTCT_ARV Sum of Regimen Type disaggregates 2015 9,218
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 9,218
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 10,241
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 9,218
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 3,597
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 5,623
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 9,220
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 9,218
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 10,415
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 5,207
PMTCT_STAT By: Known positives at entry 2015 4,002
PMTCT_STAT By: Number of new positives identified 2015 6,404
PMTCT_STAT Number of new ANC and L&D clients 2015 94,168
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 80,048
PMTCT_STAT Sum of Positives Status disaggregates 2015 10,406
PMTCT_STAT_NGI By: Known positives at entry 2015 4,002
PMTCT_STAT_NGI By: Number of new positives identified 2015 6,404
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 94,168
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 80,048
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 10,406
SITE_SUPP By program area/support type: Care and Support Direct Service Delivery (DSD) 2015 80
SITE_SUPP By program area/support type: Care and Support Technical Assistance-only (TA) 2015 78
SITE_SUPP By program area/support type: HTC Technical Assistance-only (TA) 2015 80
SITE_SUPP By program area/support type: PMTCT Direct Service Delivery (DSD) 2015 78
SITE_SUPP By program area/support type: PMTCT Technical Assistance-only (TA) 2015 78
SITE_SUPP By program area/support type: TB/HIV Direct Service Delivery (DSD) 2015 78
SITE_SUPP By program area/support type: TB/HIV Technical Assistance-only (TA) 2015 78
SITE_SUPP By program area/support type: Treatment Direct Service Delivery (DSD) 2015 80
SITE_SUPP Number of unique sites supported by PEPFAR 2015 80
TX_CURR Aggregated Age/Sex: <1 Female 2015 2,250
TX_CURR Aggregated Age/Sex: <1 Male 2015 1,233
TX_CURR Aggregated Age/Sex: <15 Female 2015 7,805
TX_CURR Aggregated Age/Sex: <15 Male 2015 4,273
TX_CURR Aggregated Age/Sex: 15+ Female 2015 99,207
TX_CURR Aggregated Age/Sex: 15+ Male 2015 54,241
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 165,526
TX_CURR Sum of Aggregated Age/Sex <15 2015 12,078
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 153,448
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 165,526
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 2,250
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 1,233
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 7,805
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 4,273
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 99,207
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 54,241
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 165,526
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 12,078
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 153,448
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 165,526
TX_DIST Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District 2015 7
TX_DIST Total number of PEPFAR supported District Health Offices 2015 7
TX_NEW Aggregated Grouping by Age: <1 Male 2015 166
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 166
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 1,659
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 1,659
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 14,092
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 7,841
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 25,251
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 25,251
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 20,706
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 25,251
TX_SITE By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 66
TX_SITE By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites 2015 66
TX_SITE Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 66
TX_SITE Sum of Numerator Site Support Type disaggregates 2015 66
TX_SITE Total number of PEPFAR-supported ART sites 2015 66
TX_SITE_den Sum of Denominator Site Support Type disaggregates 2015 66
Cross Cutting Budget Categories and Known Amounts Total: $100,000
Human Resources for Health $50,000
Motor Vehicles: Purchased $50,000
Key Issues Identified in Mechanism
Child Survival Activities
Safe Motherhood
Tuberculosis